Positive Trending Data from 57 Per-Protocol Patients Suggest NE3107 is Biologically Active and May Have Impact on Cognitive, Functional, and Biomarker.
BioVie Inc (NASDAQ: BIVI) shares are trading lower after the company released an analysis of unblinded, topline efficacy data from its Phase 3 trial of NE3107 for mild to
29.11.2023 - Positive Trending Data from 57 Per-Protocol Patients Suggest NE3107 is Biologically Active and May Have Impact on Cognitive, Functional, and Biomarker Endpoints Sponsor Identified Issues Relating to Significant GCP Violations and Protocol .
Cassava Sciences: Likely Potential Opportunity From Phase 3 Readout (NASDAQ:SAVA) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.